# Pulse Biosciences, Inc.: financial statements, quarterly

PLSE · Nasdaq · CIK 1625101 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/plse.md) · [Financials](/companies/plse/financials.md) · [Filings](/companies/plse/filings.md) · [Insiders](/companies/plse/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/plse/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001437749-24-032614.md) | [0.0 d](/filings/0001437749-25-009932.md) | [0.0](/filings/0001437749-25-015565.md) | [0.0](/filings/0001437749-25-026209.md) | [0.0](/filings/0001437749-25-033354.md) | [0.0 d](/filings/0001437749-26-004724.md) | [0.0](/filings/0001437749-26-016897.md) | [0.0](/filings/0001437749-26-026288.md) | [0.1](/filings/0001437749-25-033354.md) | [0.3 d](/filings/0001437749-26-004724.md) | [0.4](/filings/0001437749-26-016897.md) | [0.4](/filings/0001437749-26-026288.md) |
| Cost of revenue | $m | [0.0](/filings/0001437749-23-031686.md) | [0.0 d](/filings/0001437749-24-009815.md) | not reported | not reported | [0.0](/filings/0001437749-25-033354.md) | [0.0 d](/filings/0001437749-26-004724.md) | [0.0](/filings/0001437749-26-016897.md) | [0.0](/filings/0001437749-26-026288.md) | [0.3](/filings/0001437749-25-033354.md) | [0.3 d](/filings/0001437749-26-004724.md) | [0.4](/filings/0001437749-26-016897.md) | [0.3](/filings/0001437749-26-026288.md) |
| Research and development | $m | [7.5](/filings/0001437749-24-032614.md) | [7.8 d](/filings/0001437749-25-009932.md) | [6.7](/filings/0001437749-25-015565.md) | [7.2](/filings/0001437749-25-026209.md) | [7.7](/filings/0001437749-25-033354.md) | [10.7 d](/filings/0001437749-26-004724.md) | [10.3](/filings/0001437749-26-016897.md) | [12.1](/filings/0001437749-26-026288.md) | [11.4](/filings/0001437749-25-033354.md) | [10.9 d](/filings/0001437749-26-004724.md) | [12.6](/filings/0001437749-26-016897.md) | [17.0](/filings/0001437749-26-026288.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | [6.0](/filings/0001437749-25-033354.md) | [9.6 d](/filings/0001437749-26-004724.md) | [7.7](/filings/0001437749-26-016897.md) | [8.2](/filings/0001437749-26-026288.md) | [8.8](/filings/0001437749-25-033354.md) | [7.3 d](/filings/0001437749-26-004724.md) | [6.6](/filings/0001437749-26-016897.md) | [8.5](/filings/0001437749-26-026288.md) |
| Operating income | $m | [(11.3)](/filings/0001437749-24-032614.md) | [(12.5) d](/filings/0001437749-25-009932.md) | [(10.6)](/filings/0001437749-25-015565.md) | [(11.7)](/filings/0001437749-25-026209.md) | [(13.7)](/filings/0001437749-25-033354.md) | [(20.3) d](/filings/0001437749-26-004724.md) | [(18.0)](/filings/0001437749-26-016897.md) | [(20.3)](/filings/0001437749-26-026288.md) | [(20.4)](/filings/0001437749-25-033354.md) | [(18.3) d](/filings/0001437749-26-004724.md) | [(19.2)](/filings/0001437749-26-016897.md) | [(25.3)](/filings/0001437749-26-026288.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001437749-24-032614.md) | [0.0 d](/filings/0001437749-25-009932.md) | [0.0](/filings/0001437749-25-015565.md) | [0.0](/filings/0001437749-25-026209.md) | [0.0](/filings/0001437749-24-032614.md) | [0.0 d](/filings/0001437749-26-004724.md) | [0.0](/filings/0001437749-25-015565.md) | [0.0](/filings/0001437749-25-026209.md) | not reported | not reported | not reported | not reported |
| Net income | $m | [(10.6)](/filings/0001437749-24-032614.md) | [(11.9) d](/filings/0001437749-25-009932.md) | [(10.1)](/filings/0001437749-25-015565.md) | [(11.4)](/filings/0001437749-25-026209.md) | [(12.7)](/filings/0001437749-25-033354.md) | [(19.4) d](/filings/0001437749-26-004724.md) | [(16.8)](/filings/0001437749-26-026288.md) | [(19.2)](/filings/0001437749-26-026288.md) | [(19.4)](/filings/0001437749-25-033354.md) | [(17.4) d](/filings/0001437749-26-004724.md) | [(18.6)](/filings/0001437749-26-026288.md) | [(24.7)](/filings/0001437749-26-026288.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.19)](/filings/0001437749-24-032614.md) | not reported | [(0.18)](/filings/0001437749-25-015565.md) | [(0.20)](/filings/0001437749-25-026209.md) | [(0.21)](/filings/0001437749-25-033354.md) | not reported | [(0.25)](/filings/0001437749-26-016897.md) | [(0.28)](/filings/0001437749-26-026288.md) | [(0.29)](/filings/0001437749-25-033354.md) | not reported | [(0.27)](/filings/0001437749-26-016897.md) | [(0.36)](/filings/0001437749-26-026288.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [50.4](/filings/0001437749-23-031686.md) | [44.4](/filings/0001437749-25-009932.md) | [34.9](/filings/0001437749-24-015092.md) | [26.2](/filings/0001437749-24-027213.md) | [79.0](/filings/0001437749-24-032614.md) | [118](/filings/0001437749-26-004724.md) | [119](/filings/0001437749-25-015565.md) | [106](/filings/0001437749-25-026209.md) | [95.2](/filings/0001437749-25-033354.md) | [80.7](/filings/0001437749-26-026288.md) | [68.3](/filings/0001437749-26-016897.md) | [102](/filings/0001437749-26-026288.md) |
| Current assets | $m | [51.6](/filings/0001437749-23-031686.md) | [45.3](/filings/0001437749-25-009932.md) | [35.8](/filings/0001437749-24-015092.md) | [27.2](/filings/0001437749-24-027213.md) | [80.4](/filings/0001437749-24-032614.md) | [119](/filings/0001437749-26-004724.md) | [121](/filings/0001437749-25-015565.md) | [108](/filings/0001437749-25-026209.md) | [97.2](/filings/0001437749-25-033354.md) | [83.4](/filings/0001437749-26-026288.md) | [71.1](/filings/0001437749-26-016897.md) | [106](/filings/0001437749-26-026288.md) |
| Total assets | $m | [65.9](/filings/0001437749-23-031686.md) | [59.2](/filings/0001437749-25-009932.md) | [49.2](/filings/0001437749-24-015092.md) | [40.4](/filings/0001437749-24-027213.md) | [93.0](/filings/0001437749-24-032614.md) | [132](/filings/0001437749-26-004724.md) | [133](/filings/0001437749-25-015565.md) | [120](/filings/0001437749-25-026209.md) | [109](/filings/0001437749-25-033354.md) | [94.5](/filings/0001437749-26-026288.md) | [81.6](/filings/0001437749-26-016897.md) | [116](/filings/0001437749-26-026288.md) |
| Current liabilities | $m | [5.4](/filings/0001437749-23-031686.md) | [6.7](/filings/0001437749-25-009932.md) | [5.1](/filings/0001437749-24-015092.md) | [6.0](/filings/0001437749-24-027213.md) | [6.7](/filings/0001437749-24-032614.md) | [10.1](/filings/0001437749-26-004724.md) | [7.8](/filings/0001437749-25-015565.md) | [9.0](/filings/0001437749-25-026209.md) | [9.7](/filings/0001437749-25-033354.md) | [7.9](/filings/0001437749-26-026288.md) | [9.8](/filings/0001437749-26-016897.md) | [11.0](/filings/0001437749-26-026288.md) |
| Total liabilities | $m | [13.8](/filings/0001437749-23-031686.md) | [14.8](/filings/0001437749-25-009932.md) | [12.9](/filings/0001437749-24-015092.md) | [13.5](/filings/0001437749-24-027213.md) | [13.9](/filings/0001437749-24-032614.md) | [17.6](/filings/0001437749-26-004724.md) | [14.9](/filings/0001437749-25-015565.md) | [15.8](/filings/0001437749-25-026209.md) | [16.1](/filings/0001437749-25-033354.md) | [13.9](/filings/0001437749-26-026288.md) | [15.3](/filings/0001437749-26-016897.md) | [16.1](/filings/0001437749-26-026288.md) |
| Shareholders' equity | $m | [52.1](/filings/0001437749-24-032614.md) | [44.4](/filings/0001437749-26-004724.md) | [36.3](/filings/0001437749-25-026209.md) | [27.0](/filings/0001437749-25-033354.md) | [79.1](/filings/0001437749-25-033354.md) | [115](/filings/0001437749-26-026288.md) | [118](/filings/0001437749-26-026288.md) | [104](/filings/0001437749-26-026288.md) | [92.7](/filings/0001437749-25-033354.md) | [80.7](/filings/0001437749-26-026288.md) | [66.3](/filings/0001437749-26-026288.md) | [99.5](/filings/0001437749-26-026288.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(10.5) d](/filings/0001437749-24-032614.md) | [(6.8) d](/filings/0001437749-25-009932.md) | [(9.8)](/filings/0001437749-25-015565.md) | [(8.4) d](/filings/0001437749-25-026209.md) | [(9.0) d](/filings/0001437749-25-033354.md) | [(9.1) d](/filings/0001437749-26-004724.md) | [(13.5)](/filings/0001437749-26-016897.md) | [(12.8) d](/filings/0001437749-26-026288.md) | [(13.0) d](/filings/0001437749-25-033354.md) | [(14.8) d](/filings/0001437749-26-004724.md) | [(14.6)](/filings/0001437749-26-016897.md) | [(18.7) d](/filings/0001437749-26-026288.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001437749-24-032614.md) | [0.0 d](/filings/0001437749-25-009932.md) | [0.0](/filings/0001437749-25-015565.md) | [0.0 d](/filings/0001437749-25-026209.md) | [0.0 d](/filings/0001437749-25-033354.md) | [0.1 d](/filings/0001437749-26-004724.md) | [0.0](/filings/0001437749-26-016897.md) | [0.1 d](/filings/0001437749-26-026288.md) | [0.1 d](/filings/0001437749-25-033354.md) | [0.1 d](/filings/0001437749-26-004724.md) | [0.0](/filings/0001437749-26-016897.md) | [0.1 d](/filings/0001437749-26-026288.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [26.5](/filings/0001625101-22-000061.md) | [29.6](/filings/0001625101-22-000067.md) | [31.5](/filings/0001625101-22-000061.md) | [37.2](/filings/0001625101-22-000067.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 71,322,607 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001437749-26-026288.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.